January 20, 2022 -- Charles River Laboratories and Valo Health have formed a multiyear strategic partnership to offer a transformative, artificial intelligence (AI)-enabled drug discovery and development platform.
The collaboration intends to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for client preferences, the companies said. The partnership's combined offerings will utilize Valo's Opal platform for small molecule development, which leverages a "closed-loop," in-silico experimental platform that rapidly iterates using program data to identify novel compounds, and Charles River's capabilities in discovery optimization -- including medicinal chemistry, absorption, distribution, metabolism and excretion, biology, pharmacology, and, ultimately, safety testing and investigational new drug submission.
The combined offering will be launched in the first half of 2022 and will be available exclusively from Charles River.
No financial details were disclosed.
Copyright © 2022 scienceboard.net